Comparison of baseline demographic and clinical characteristics between patients with high- and non–high-risk CLL/SLL before applying IPTW
| . | High-risk patients (n = 969) . | Non–high-risk patients (n = 273) . | P value . |
|---|---|---|---|
| Baseline demographic characteristics | |||
| Age, mean (SD), y∗ | 70.0 (10.2) | 70.8 (9.0) | .59 |
| Age group, n (%), y∗ | .73 | ||
| 32-64 | 261 (26.9) | 67 (24.5) | |
| 65-69 | 164 (16.9) | 49 (17.9) | |
| 70-74 | 173 (17.9) | 50 (18.3) | |
| 75-79 | 163 (16.8) | 50 (18.3) | |
| ≥80 | 208 (21.5) | 57 (20.9) | |
| Male, n (%) | 618 (63.8) | 154 (56.4) | .03† |
| Race, n (%) | .10 | ||
| White | 698 (72.0) | 204 (74.7) | |
| Black or African American | 110 (11.4) | 17 (6.2) | |
| Other‡ | 86 (8.9) | 27 (9.9) | |
| Unknown | 75 (7.7) | 25 (9.2) | |
| Geographic region within the Unites States, n (%) | .44 | ||
| South | 396 (40.9) | 113 (41.1) | |
| Northeast | 210 (21.7) | 72 (26.4) | |
| Midwest | 142 (14.7) | 35 (12.8) | |
| West | 128 (13.2) | 30 (11.0) | |
| Unknown | 93 (9.6) | 23 (8.4) | |
| Baseline clinical characteristic | |||
| Disease type, n (%) | .15 | ||
| CLL | 805 (83.1) | 240 (87.9) | |
| CLL/SLL | 116 (12.0) | 23 (8.4) | |
| SLL | 48 (5.0) | 10 (3.7) | |
| Payer category, n (%) | .66 | ||
| Commercial | 332 (34.3) | 87 (31.9) | |
| Medicare Plus | 293 (30.2) | 84 (30.8) | |
| Medicare | 70 (7.2) | 24 (8.8) | |
| Other plus | 48 (5.0) | 10 (3.7) | |
| Other single | 41 (4.2) | 14 (5.1) | |
| Medicaid | 6 (0.6) | 0 (0.0) | |
| Unknown | 179 (18.5) | 54 (19.8) | |
| ECOG PS score, n (%) | .21 | ||
| 0-1 | 662 (68.3) | 199 (72.9) | |
| 2 | 55 (5.7) | 20 (7.3) | |
| 3-4 | 13 (1.3) | 5 (1.8) | |
| Unknown | 239 (24.7) | 49 (17.9) | |
| Quan-CCI score, mean (SD) | 0.2 (0.6) | 0.1 (0.4) | .36 |
| Practice type, n (%) | .25 | ||
| Community | 888 (91.6) | 256 (93.8) | |
| Academic | 81 (8.4) | 17 (6.2) | |
| Index year, n (%) | .27 | ||
| 2016 | 96 (9.9) | 22 (8.1) | |
| 2017 | 139 (14.3) | 30 (11.0) | |
| 2018 | 165 (17.0) | 36 (13.2) | |
| 2019 | 235 (24.3) | 75 (27.5) | |
| 2020 | 166 (17.1) | 56 (20.5) | |
| 2021 | 126 (13.0) | 42 (15.4) | |
| 2022 | 42 (4.3) | 12 (4.4) | |
| Rai stage, n (%) | .22 | ||
| 0 | 260 (26.8) | 92 (33.7) | |
| I | 145 (15.0) | 41 (15.0) | |
| II | 68 (7.0) | 12 (4.4) | |
| III | 72 (7.4) | 17 (6.2) | |
| IV | 75 (7.7) | 17 (6.2) | |
| Unknown | 349 (36.0) | 94 (34.4) | |
| Time from diagnosis to index drug initiation, mean (SD), mo | 35.0 (48.0) | 64.4 (73.2) | <.0001† |
| . | High-risk patients (n = 969) . | Non–high-risk patients (n = 273) . | P value . |
|---|---|---|---|
| Baseline demographic characteristics | |||
| Age, mean (SD), y∗ | 70.0 (10.2) | 70.8 (9.0) | .59 |
| Age group, n (%), y∗ | .73 | ||
| 32-64 | 261 (26.9) | 67 (24.5) | |
| 65-69 | 164 (16.9) | 49 (17.9) | |
| 70-74 | 173 (17.9) | 50 (18.3) | |
| 75-79 | 163 (16.8) | 50 (18.3) | |
| ≥80 | 208 (21.5) | 57 (20.9) | |
| Male, n (%) | 618 (63.8) | 154 (56.4) | .03† |
| Race, n (%) | .10 | ||
| White | 698 (72.0) | 204 (74.7) | |
| Black or African American | 110 (11.4) | 17 (6.2) | |
| Other‡ | 86 (8.9) | 27 (9.9) | |
| Unknown | 75 (7.7) | 25 (9.2) | |
| Geographic region within the Unites States, n (%) | .44 | ||
| South | 396 (40.9) | 113 (41.1) | |
| Northeast | 210 (21.7) | 72 (26.4) | |
| Midwest | 142 (14.7) | 35 (12.8) | |
| West | 128 (13.2) | 30 (11.0) | |
| Unknown | 93 (9.6) | 23 (8.4) | |
| Baseline clinical characteristic | |||
| Disease type, n (%) | .15 | ||
| CLL | 805 (83.1) | 240 (87.9) | |
| CLL/SLL | 116 (12.0) | 23 (8.4) | |
| SLL | 48 (5.0) | 10 (3.7) | |
| Payer category, n (%) | .66 | ||
| Commercial | 332 (34.3) | 87 (31.9) | |
| Medicare Plus | 293 (30.2) | 84 (30.8) | |
| Medicare | 70 (7.2) | 24 (8.8) | |
| Other plus | 48 (5.0) | 10 (3.7) | |
| Other single | 41 (4.2) | 14 (5.1) | |
| Medicaid | 6 (0.6) | 0 (0.0) | |
| Unknown | 179 (18.5) | 54 (19.8) | |
| ECOG PS score, n (%) | .21 | ||
| 0-1 | 662 (68.3) | 199 (72.9) | |
| 2 | 55 (5.7) | 20 (7.3) | |
| 3-4 | 13 (1.3) | 5 (1.8) | |
| Unknown | 239 (24.7) | 49 (17.9) | |
| Quan-CCI score, mean (SD) | 0.2 (0.6) | 0.1 (0.4) | .36 |
| Practice type, n (%) | .25 | ||
| Community | 888 (91.6) | 256 (93.8) | |
| Academic | 81 (8.4) | 17 (6.2) | |
| Index year, n (%) | .27 | ||
| 2016 | 96 (9.9) | 22 (8.1) | |
| 2017 | 139 (14.3) | 30 (11.0) | |
| 2018 | 165 (17.0) | 36 (13.2) | |
| 2019 | 235 (24.3) | 75 (27.5) | |
| 2020 | 166 (17.1) | 56 (20.5) | |
| 2021 | 126 (13.0) | 42 (15.4) | |
| 2022 | 42 (4.3) | 12 (4.4) | |
| Rai stage, n (%) | .22 | ||
| 0 | 260 (26.8) | 92 (33.7) | |
| I | 145 (15.0) | 41 (15.0) | |
| II | 68 (7.0) | 12 (4.4) | |
| III | 72 (7.4) | 17 (6.2) | |
| IV | 75 (7.7) | 17 (6.2) | |
| Unknown | 349 (36.0) | 94 (34.4) | |
| Time from diagnosis to index drug initiation, mean (SD), mo | 35.0 (48.0) | 64.4 (73.2) | <.0001† |